Sodium Salt of Fomesafen Tolerance Summary Report

Tolerance Granted(ppm)	Commodity	PC Code	CAS #	Ingredient Name	Current Status	Tolerance Type	CFR Citation	Codex

(mg/kg)	Canada

(mg/kg)

residue=

5-[2-chloro-4-

(trifluoromethyl)

phenoxy]-N-

(methylsulfonyl)-2-

nitrobenzamide

	Mexico

(mg/kg)

residue=

fomesafen

.025	COTTON, GIN BYPRODUCTS	123802	108731-70-0	Sodium salt of fomesafen Established (03-May-2006)	Permanent Tolerance	180.433	None

.025	BEAN, SNAP, SUCCULENT	123802	108731-70-0	Sodium salt of fomesafen Established (03-May-2006)	Permanent Tolerance	180.433

0.05

(snap beans)

	.025	COTTON, UNDELINTED SEED	123802	108731-70-0	Sodium salt of fomesafen	Established (03-May-2006)	Permanent Tolerance	180.433

	.05	SOYBEAN	123802	108731-70-0	Sodium salt of fomesafen	Established (03-May-2006)	Permanent

Tolerance	180.433

0.05	0.05

.025	BEAN, DRY	123802	108731-70-0	Sodium salt of fomesafen	Established (03-May-2006)	Permanent

Tolerance	180.433

0.05

LIMA BEAN

0.05


[Federal Register: February 8, 2007 (Volume 72, Number 26)]
[Notices]
[Page 6017]
[DOCID:fr08fe07-87]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[File No. 500-1]

In the Matter of CyberKey Solutions, Inc.; Order of Suspension of
Trading

    It appears to the Securities and Exchange Commission that there is
a lack of current and accurate information concerning the securities of
CyberKey Solutions, Inc. (``CyberKey'') because of questions regarding
the accuracy of assertions made by CyberKey, and others, in press
releases and other public statements to investors, concerning among
other things: (1) Contracts with the Department of Homeland Security
and/or other government agencies, (2) revenues received pursuant to
those contracts, and (3) accounts receivable generated by those
contracts.
    The Commission is of the opinion that the public interest and the
protection of investors require a suspension of trading in the
securities of the above-listed company.
    Therefore, it is ordered, pursuant to Section 12(k) of the
Securities Exchange Act of 1934, that trading in the above-listed
company is suspended for the period from 9:30 a.m. EST February 5, 2007
through 11:59 p.m. EST, on February 16, 2007.

    By the Commission.
Nancy M. Morris,
Secretary.
[FR Doc. 07-552 Filed 2-5-07; 11:18 am]

BILLING CODE 8010-01-P


[Federal Register Volume 86, Number 61 (Thursday, April 1, 2021)]
[Notices]
[Pages 17165-17167]
[FR Doc No: 2021-06708]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2021-N-0270]

Endocrinologic and Metabolic Drugs Advisory Committee; Notice of
Meeting; Establishment of a Public Docket; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; establishment of a public docket; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming
public advisory committee meeting of the Endocrinologic and Metabolic
Drugs Advisory Committee. The general function of the committee is to
provide advice and recommendations to FDA on regulatory issues. The
meeting will be open to the public. FDA is establishing a docket for
public comment on this document.

DATES: The meeting will be held on May 27, 2021, from 9 a.m. to 5:30
p.m. Eastern Time.

ADDRESSES: Please note that due to the impact of this COVID-19
pandemic, all meeting participants will be joining this advisory
committee meeting via an online teleconferencing platform. Answers to
commonly asked questions about FDA advisory committee meetings may be
accessed at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.
    FDA is establishing a docket for public comment on this meeting.
The docket number is FDA-2021-N-0270. The docket will close on May 26,
2021. Submit either electronic or written comments on this public
meeting by May 26, 2021. Please note that late, untimely filed comments
will not be considered. Electronic comments must be submitted on or
before May 26, 2021. The https://www.regulations.gov electronic filing
system will accept comments until 11:59 p.m. Eastern Time at the end of
May 26, 2021. Comments received by mail/hand delivery/courier (for
written/paper submissions) will be considered timely if they are
postmarked or the delivery service acceptance receipt is on or before
that date.
    Comments received on or before May 13, 2021, will be provided to
the committee. Comments received after that date will be taken into
consideration by FDA. In the event that the meeting is cancelled, FDA
will continue to evaluate any relevant applications or information, and
consider any comments submitted to the docket, as appropriate.
    You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2021-N-0270 for ``Endocrinologic and Metabolic Drugs Advisory
Committee; Notice of Meeting; Establishment of a Public Docket; Request
for Comments.'' Received comments, those filed in a timely manner (see
ADDRESSES), will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday,<PHONE_NUMBER>.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' FDA will review
this copy, including the claimed confidential information, in its
consideration of comments. The second copy, which will have the claimed
confidential information redacted/blacked out, will be available for
public viewing and posted on https://www.regulations.gov. Submit both
copies to the Dockets Management Staff. If you do not wish your name
and contact information be made publicly available, you can provide
this information on the cover sheet and not in the body of your
comments and you must identify the information as ``confidential.'' Any
information marked as ``confidential'' will not be disclosed except in
accordance with 21 CFR 10.20 and other applicable disclosure law. For
more information about FDA's posting of comments to public dockets, see
80 FR 56469, September 18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852,<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: LaToya Bonner, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002,
email<EMAIL_ADDRESS>301-796-2855, or FDA Advisory Committee
Information Line, 1-800-741-8138<PHONE_NUMBER> in the Washington, DC
area). A notice in the Federal Register about last-minute modifications
that impact a previously announced advisory committee meeting cannot
always be published quickly enough to provide timely notice. Therefore,
you should always check FDA's website at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate
advisory committee meeting link, or call the advisory committee
information line to learn about possible modifications before coming to
the meeting.

SUPPLEMENTARY INFORMATION:
    Agenda: The meeting presentations will be heard, viewed, captioned,
and recorded through an online teleconferencing platform. The committee
will discuss the safety and efficacy of biologics license application
(BLA) 761183, for teplizumab intravenous infusion, submitted by
Provention Bio, Inc. The proposed indication is for the delay or
prevention of clinical type 1 diabetes mellitus in at-risk (Stage 2)
individuals.
    FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its website prior to the meeting, the
background material will be made publicly available on FDA's website at
the time of the advisory committee meeting. Background material and the
link to the online teleconference meeting room will be available at
https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll
down to the

appropriate advisory committee meeting link. The meeting will include
slide presentations with audio components to allow the presentation of
materials in a manner that most closely resembles an in-person advisory
committee meeting.
    Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
All electronic and written submissions submitted to the Docket (see
ADDRESSES) on or before May 13, 2021, will be provided to the
committee. Oral presentations from the public will be scheduled between
approximately 1:30 p.m. and 2:30 p.m. Eastern Time. Those individuals
interested in making formal oral presentations should notify the
contact person and submit a brief statement of the general nature of
the evidence or arguments they wish to present, the names and addresses
of proposed participants, and an indication of the approximate time
requested to make their presentation on or before May 5, 2021. Time
allotted for each presentation may be limited. If the number of
registrants requesting to speak is greater than can be reasonably
accommodated during the scheduled open public hearing session, FDA may
conduct a lottery to determine the speakers for the scheduled open
public hearing session. The contact person will notify interested
persons regarding their request to speak by May 6, 2021.
    For press inquiries, please contact the Office of Media Affairs at
<EMAIL_ADDRESS>or<PHONE_NUMBER>.
    FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact LaToya Bonner (see FOR FURTHER INFORMATION CONTACT) at least 7
days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our website at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).

    Dated: March 26, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2021-06708 Filed 3-31-21; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register Volume 82, Number 235 (Friday, December 8, 2017)]
[Rules and Regulations]
[Pages 57848-57849]
[FR Doc No: 2017-26406]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[EPA-R07-OAR-2017-0513; FRL-9971-68--Region 7]

Approval of Missouri Air Quality Implementation Plans;
Infrastructure SIP Requirements for the 2012 Annual Fine Particulate
Matter (PM2.5) National Ambient Air Quality Standard; Withdrawal of
Direct Final Rule

AGENCY: Environmental Protection Agency (EPA).

ACTION: Withdrawal of direct final rule.

-----------------------------------------------------------------------

SUMMARY: Due to adverse comments, the Environmental Protection Agency
(EPA) is withdrawing the direct final rule for ``Approval of Missouri
Air Quality Implementation Plans; Infrastructure SIP Requirements for
the 2012 Annual Fine Particulate Matter (PM2.5) National
Ambient Air Quality Standard'' published in the Federal Register on
October 11, 2017. Section 110 of the CAA requires that each state adopt
and submit a SIP for the implementation, maintenance, and enforcement
of each new or revised NAAQS promulgated by

EPA. These SIPs are commonly referred to as ``infrastructure'' SIPs.
The infrastructure requirements are designed to ensure that the
structural components of each state's air quality management program
are adequate to meet the state's responsibilities under the CAA.

DATES: The direct final rule published at 82 FR 47147 on October 11,
2017 is withdrawn effective December 8, 2017.

FOR FURTHER INFORMATION CONTACT: Tracey Casburn, Environmental
Protection Agency, Air Planning and Development Branch, 11201 Renner
Boulevard, Lenexa, Kansas 66219 at<PHONE_NUMBER>, or by email at
[email protected].

SUPPLEMENTARY INFORMATION: Due to adverse comments, EPA is withdrawing
the direct final rule to approve the states ``infrastructure'' SIP
revision for the 2012 PM2.5 NAAQS. In the direct final rule
published on October 11, 2017, (82 FR 47147), EPA stated that if it
received adverse comment by November 13, 2017, the rule would be
withdrawn and not take effect. The direct final rule was an approval of
a State Implementation Plan (SIP) revision from the State of Missouri
for the 2012 PM2.5 National Ambient Air Quality Standard
(NAAQS). The direct final approval action also included the approval of
Missouri State Statue section 105.483(5) RSMo 2014, and Missouri State
Statue section 105.485 RSMo 2014 into the SIP. These two statutes
address aspects of the infrastructure requirements relating to
conflicts of interest as found in section 128 of the CAA. EPA received
adverse comments. EPA will address the comments in a subsequent final
action based upon the proposed action also published on October 11,
2017, at 82 FR 47169. EPA will not institute a second comment period on
this action.

List of Subjects in 40 CFR Part 52

    Environmental protection, Air pollution control, Incorporation by
reference, Intergovernmental relations, Nitrogen dioxide, Particulate
matter, Reporting and recordkeeping requirements, Sulfur dioxides.

    Dated: November 21, 2017.
James B. Gulliford,
Regional Administrator, Region 7.

0
Accordingly, the amendments to 40 CFR 52.1320 published on October 11,
2017 (82 FR 47147) are withdrawn effective December 8, 2017.

[FR Doc. 2017-26406 Filed 12-7-17; 8:45 am]
 BILLING CODE 6560-50-P


[Federal Register Volume 87, Number 192 (Wednesday, October 5, 2022)]
[Notices]
[Pages 60420-60421]
[FR Doc No: 2022-21540]

=======================================================================
-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Investment Company Act Release No. 34719; File No. 812-15378]

Neuberger Berman BDC LLC, et al.

September 29, 2022.
AGENCY: Securities and Exchange Commission (``Commission'' or ``SEC'').

ACTION: Notice.

-----------------------------------------------------------------------

    Notice of application for an order (``Order'') under sections 17(d)
and 57(i) of the Investment Company Act of 1940 (the ``Act'') and rule
17d-1 under the Act to permit certain joint transactions otherwise
prohibited by sections 17(d) and 57(a)(4) of the Act and rule 17d-1
under the Act.
    Summary of Application: Applicants request an order to amend a
previous order granted by the Commission that permits certain business
development companies (``BDCs'') and closed-end management investment
companies to co-invest in portfolio companies with each other and with
certain affiliated investment entities.
    Applicants: Neuberger Berman BDC LLC, Neuberger Berman Next
Generation Connectivity Fund Inc., NB Private Markets Fund II (Master)
LLC, NB Private Markets Fund III (Master) LLC, NB Crossroads Private
Markets Fund IV Holdings LLC, NB Crossroads Private Markets Fund V
Holdings LP, NB Crossroads Private Markets Fund VI Holdings LP, NB
Crossroads Private Markets Fund VII Holdings LP, NB Crossroads Private
Markets Access Fund LLC, NB Alternatives Advisers LLC, Neuberger Berman
Investment Advisers LLC, Columbia NB Crossroads Fund II LP, Golden Road
Capital Pooling L.P., MEP Opportunities Fund Holdings LP, NB--Iowa's
Public Universities LP, NB 1 PE Investment Holdings LP, NB 1911 LP, NB
AGI PE Portfolio II Fund LP, NB ASGA Fund Holdings LP, NB Ayame
Holdings LP, NB Blue Ensign Fund LP, NB Caspian Holdings LP, NB CPEG
Fund Holdings LP, NB Credit Opportunities Co-Invest Affordable Care I
LP, NB Credit Opportunities Co-Invest I LP, NB Credit Opportunities
Fund II LP, NB Credit Opportunities II Cayman LP, NB Credit
Opportunities II Co-Investment Fund (Cayman) LP, NB Credit
Opportunities II Co-Investment (Whistler) LP, NB Crossroads 23 LC
Holdings LP, NB Crossroads 23 MC Holdings LP, NB Crossroads 23 SS
Holdings LP, NB Crossroads 23 VC Holdings LP, NB Crossroads 24 LC
Holdings LP, NB Crossroads 24 MC Holdings LP, NB Crossroads 24 SS
Holdings LP, NB Crossroads 24 VC Holdings LP, NB Crossroads XXII--MC
Holdings LP, NB Crossroads XXII--VC Holdings LP, NB Crystal PE Holdings
LP, NB Direct Access Fund II LP, NB Enhanced Income Holdings LP, NB
Enhanced Income Holdings II LP, NB Enstar PE Opportunities Fund, LP, NB
Euro Crossroads 2018 Holdings SCSp, NB Euro Crossroads 2021 Holdings
SCSp, NB Flamingo Private Debt LP, NB

Flat Corner PE Holdings LP, NB Gemini Fund LP, NB Granite Private Debt
LP, NB Greencastle LP, NB Initium Infrastructure (EUR) Holdings LP, NB
Initium Infrastructure (USD) Holdings LP, NB Initium PE (EUR) Holdings
LP, NB Initium PE (USD) Holdings LP, NB Initium PE II (USD) Holdings
LP, NB Oak LP, NB PA Co-Investment Fund LP, NB PD III Holdings (LO) LP,
NB PD III Holdings (LS) LP, NB PD III Holdings (UO) LP, NB PD III
Holdings (US) LP, NB PD IV Equity LP, NB PD IV Holdings (LO-A) LP, NB
PD IV Holdings (LO-MS) LP, NB PD IV Holdings (LS-A) LP, NB PD IV
Holdings (US-A) (Levered) LP, NB PD IV Holdings (US-B) (Unlevered) LP,
NB PD IV Holdings (UO-A) LP, NB PEP Holdings Limited, NB Pinnacol
Assurance Fund LP, NB Private Debt Fund LP, NB Private Debt II Holdings
LP, NB Private Equity Credit Opportunities Holdings LP, NB Private
package lp, NB Rembrandt Holdings 2018 LP, NB Rembrandt Holdings 2020
LP, NB Rembrandt Holdings 2022 LP, NB Renaissance Partners Holdings S.a
r.l., NB RESOF Holdings LP, NB RESOF II Cayman Holdings LP, NB RESOF II
Holdings LP, NB RESOF SP1 LP, NB River City Fund LP, NB RP Co-
Investment & Secondary Fund LLC, NB RPPE Partners LP, NB SBS US 3 Fund
LP, NB Select Opps III MHF LP, NB Select Opps IV MHF LP, NB Select Opps
V MHF LP, NB SHP Fund Holdings LP, NB SI-Apollo Sengai Fund Holdings
LP, NB SOF III Holdings LP, NB SOF IV Cayman Holdings LP, NB SOF IV
Holdings LP, NB SOF V Cayman Holdings LP, NB SOF V Holdings LP, NB
Sonoran Fund Limited Partnership, NB STAR Buyout Strategy 2020 Holdings
Ltd, NB STAR Buyout Strategy 2021 Holdings Ltd, NB STAR Buyout Strategy
2022 Holdings Ltd, NB Strategic Capital LP, NB Strategic Co-Investment
Partners IV Holdings LP, NB Strategic Partnership Fund Co-Investments
LP, NB Swan Private Debt SCSp, NB TCC Strategic Holdings LP, NB TPSF EM
PE Fund LP, NB Wessex Holdings LP, NB Wildcats Fund LP, NB ZCF LP, NBAL
Holdings LP, NBFOF Impact--Holdings LP, NBPD AT Holdings (LO-A) LP,
NBPD Centennial Holdings (LO-A) LP, NBPD III Equity Co-Invest Holdings
A LP, NB-Sompo RA Holdings LP, NEUB Holdings LP, NEUB Infrastructure
Holdings LP, Neuberger Berman/New Jersey Custom Investment Fund III LP,
NYC-NorthBound Emerging Managers Program LP, NYSCRF NB Co-Investment
Fund LLC, NYSCRF NB Co-Investment Fund II LLC, Olive Cayman Holdings
Ltd, PECO-PD III BORROWER LP, SJFED Private Equity Strategic
Partnership, L.P., SJPF Private Equity Strategic Partnership, L.P.,
Soleil 2020 Cayman Holdings Ltd, Soleil 2022 EUR Cayman Holdings Ltd,
Soleil B 2022 EUR Cayman Holdings Ltd, Soleil B 2022 USD Cayman
Holdings Ltd, SunBerg PE Opportunities Fund LLC, SunBern Alternative
Opportunities Fund LLC, Toranomon Private Equity 1, L.P., NB BVK
Holdings SCSp, NB Strategic Capital II Cayman Holdings LP, NB Strategic
Capital II Holdings LP, NB Select Opps VI MHF LP, NB Central Valley
Holdings LP, and NB Impulsum (USD) Holdings LP.
    Filing Dates: The application was filed on August 5, 2022, and
amended on September 22, 2022.
    Hearing or Notification of Hearing: An order granting the requested
relief will be issued unless the Commission orders a hearing.
Interested persons may request a hearing on any application by emailing
the SEC's Secretary at [email protected] and serving the
Applicants with a copy of the request by email, if an email address is
listed for the relevant Applicant below, or personally or by mail, if a
physical address is listed for the relevant Applicant below. Hearing
requests should be received by the Commission by 5:30 p.m. on, October
24, 2022, and should be accompanied by proof of service on applicants,
in the form of an affidavit or, for lawyers, a certificate of service.
Pursuant to rule 0-5 under the Act, hearing requests should state the
nature of the writer's interest, any facts bearing upon the
desirability of a hearing on the matter, the reason for the request,
and the issues contested. Persons who wish to be notified of a hearing
may request notification by emailing the Commission's Secretary at
[email protected].

ADDRESSES: The Commission: [email protected]. Applicants: Corey
Issing, Neuberger Berman Investment Advisers LLC, at
[email protected]; Nicole M. Runyan and William J. Tuttle, Kirkland &
Ellis LLP, at [email protected].

FOR FURTHER INFORMATION CONTACT: Kieran G. Brown, Senior Counsel, or
Terri Jordan, Branch Chief, at<PHONE_NUMBER> (Division of Investment
Management, Chief Counsel's Office).

SUPPLEMENTARY INFORMATION: For Applicants' representations, legal
analysis, and conditions, please refer to Applicants' first amended and
restated application, dated September 22, 2022, which may be obtained
via the Commission's website by searching for the file number at the
top of this document, or for an Applicant using the Company name search
field, on the SEC's EDGAR system. The SEC's EDGAR system may be
searched at, http://www.sec.gov/edgar/searchedgar/legacy/companysearch.html. You may also call the SEC's Public Reference Room
at<PHONE_NUMBER>.

    For the Commission, by the Division of Investment Management,
under delegated authority.
J. Matthew DeLesDernier,
Deputy Secretary.
[FR Doc. 2022-21540 Filed 10-4-22; 8:45 am]
BILLING CODE 8011-01-P


[Federal Register: September 22, 2008 (Volume 73, Number 184)]
[Notices]
[Page 54586]
[DOCID:fr22se08-35]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. EF08-5171-000]

Western Area Power Administration; Notice of Filing

September 15, 2008.
    Take notice that on September 8, 2008, the Deputy Secretary of the
Department of Energy submitted Rate Order No. WAPA-137, confirmed and
approved on an interim basis, effective October, 2008, Rate Schedule
SLIP-F9 for firm power from Salt Lake City Area Integrated Projects,
SP-PTP7 for firm point-to-point transmission, SP-NW3 for network
integration transmission service, SP-NFT6 for non-firm transmission on
the Colorado River Storage Project and SP-SD3, SP-RS3, SP-EI3, SP-FR3
and SP-SSR for ancillary services, and submitted for confirmation and
approval on a final basis, under the authority vested in the Commission
by Delegation Order No. 00-037.00, Rate Schedules SLIP-F9, SP-PTP7, SP-
NW3, SP-NFT6, SP-DS3, SP-RS3, SP-EI3, and SP-SSR3, effective October 1,
2008 and ending September 30, 2013.
    Any person desiring to intervene or to protest this filing must
file in accordance with Rules 211 and 214 of the Commission's Rules of
Practice and Procedure (18 CFR 385.211, 385.214). Protests will be
considered by the Commission in determining the appropriate action to
be taken, but will not serve to make protestants parties to the
proceeding. Any person wishing to become a party must file a notice of
intervention or motion to intervene, as appropriate. Such notices,
motions, or protests must be filed on or before the comment date. On or
before the comment date, it is not necessary to serve motions to
intervene or protests on persons other than the Applicant.
    The Commission encourages electronic submission of protests and
interventions in lieu of paper using the ``eFiling'' link at http://
www.ferc.gov. Persons unable to file electronically should submit an
original and 14 copies of the protest or intervention to the Federal
Energy Regulatory Commission, 888 First Street, NE., Washington, DC
20426.
    This filing is accessible on-line at http://www.ferc.gov, using the
``eLibrary'' link and is available for review in the Commission's
Public Reference Room in Washington, DC. There is an ``eSubscription''
link on the Web site that enables subscribers to receive e-mail
notification when a document is added to a subscribed docket(s). For
assistance with any FERC Online service, please e-mail
<EMAIL_ADDRESS>or call<PHONE_NUMBER> (toll free). For
TTY, call<PHONE_NUMBER>.
    Comment Date: 5 p.m. Eastern Time on October 8, 2008.

Kimberly D. Bose,
Secretary.
[FR Doc. E8-22007 Filed 9-19-08; 8:45 am]

BILLING CODE 6717-01-P


[Federal Register Volume 84, Number 214 (Tuesday, November 5, 2019)]
[Rules and Regulations]
[Page 59525]
[FR Doc No: 2019-24132]

-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

33 CFR Part 100

[Docket No. USCG-2019-0728]

Special Local Regulation: Seminole Hard Rock Winterfest Holiday
Boat Parade

AGENCY: Coast Guard, DHS.

ACTION: Notice of enforcement of regulation.

-----------------------------------------------------------------------

SUMMARY: The Coast Guard will enforce a special local regulation on
December 14, 2019 to provide for the safety and security of navigable
waterways during the Seminole Hard Rock Winterfest Holiday Boat Parade.
During the enforcement period, all non-participant persons and vessels
will be prohibited from entering, transiting, anchoring in, or
remaining within the regulated area unless authorized by the Captain of
the Port Miami or a designated representative. The operator of any
vessel in the regulated area must comply with instructions from the
Coast Guard or designated representative.

DATES: The regulation in 33 CFR 100.701, Table to Sec.  100.701, Line
10 will be enforced on December 14, 2019 from 6:30 p.m. through 11:00
p.m.

FOR FURTHER INFORMATION CONTACT: If you have questions about this
notice of enforcement, call or email Mr. Omar Beceiro, Sector Miami
Waterways Management Division, U.S. Coast Guard: Telephone: 305-535-
4317, Email<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: The Coast Guard will enforce a special local
regulation for the Seminole Hard Rock Winterfest Holiday Boat Parade
published in 33 CFR 100.701, Table to Sec.  100.701, Line 10 on
December 14, 2019 from 6:30 p.m. through 11:00 p.m. This action is
being taken to provide for the safety and security of navigable
waterways during this one-day event. Our regulation for marine events
within the Seventh Coast Guard District, Sec.  100.701, specifies the
location of the special local regulation for the Seminole Hard Rock
Winterfest Holiday Boat Parade, which encompasses a 50-yard, moving
buffer zone around the parade as it travels along the New River and
Intracoastal Waterway in Ft. Lauderdale, FL. Only event sponsor
designated participants and official patrol vessels will be allowed to
enter the regulated area. Spectators may contact the Coast Guard Patrol
Commander to request permission to pass through the regulated area. If
permission is granted, spectators must pass directly through the
regulated area at a safe speed without loitering.
    In addition to this notice of enforcement in the Federal Register,
the Coast Guard will inform the public through Local Notice to Mariners
and marine information broadcasts at least 24 hours in advance of the
enforcement of the special local regulation.

    Dated: October 31, 2019.
J.F. Burdian,
Captain, U.S. Coast Guard, Captain of the Port Miami.
[FR Doc. 2019-24132 Filed 11-4-19; 8:45 am]
 BILLING CODE 9110-04-P


From:
"David Ailor"<EMAIL_ADDRESS>Sent:
Fri, 19 Aug 2022 15:19:16
To:
<EMAIL_ADDRESS>"'French; Chuck'"<EMAIL_ADDRESS><EMAIL_ADDRESS>"'Jones; DonnaLee'"<EMAIL_ADDRESS><EMAIL_ADDRESS>"'Mcginn; Kevin'"<EMAIL_ADDRESS>"'GABRIELLE RAYMOND'"<EMAIL_ADDRESS>"'Shappley; Ned'"<EMAIL_ADDRESS>Subject:
RE: DRAFT LISTS OF COETF AND EPA "DO-OUTS" FROM YESTERDAY'S CALL ON 114 TESTING
Hello again, Donna Lee.

I'm following up on two of the three COETF "do-outs" from our Tuesday, August 9 call to discuss the Coke Ovens ICR.  The two do-outs are (1) "Provide close-up images of battery bench showing safety hazards  -  tight spaces, moving equipment, etc." and (2) "Provide OSHA reports on previous injuries/fatalities."  What we are providing on each of these is discussed below:

1. Provide close-up images of battery bench showing safety hazards  -  tight spaces, moving equipment, etc.  During the August 9 call, EPA requested close-up images of the battery bench showing the potential safety hazards, including narrow spaces and areas where there is moving equipment on the bench.  Two example photos are included in the attached ".pdf" file (see "COETF Example Bench Photos.pdf").

2. Provide OSHA reports on previous injuries/fatalities.  EPA also requested that the COETF provide examples of OSHA incident reports for accidents on coke battery benches.  A ".pdf" file listing several examples is attached (see "Accident Report Detail _ Occupational Safety and Health Administration (SIC 3312).pdf").

Lastly, two of EPA's "do-outs" from the August 9 call are a "Response to COETF's letter requesting changes to the ICR schedule (expedited response requested)" and a "Response to COETF's letter requesting changes to the ICR scope."  Can you please advise when EPA will be providing responses to these time-sensitive requests?  The COETF would greatly appreciate knowing as soon as possible if EPA is making changes to the ICR scope and providing the requested extensions of time.

Thanks.  And, please contact me if you have any questions.  DCA

David C. Ailor, P.E.
President
American Coke and Coal Chemicals Institute
25 Massachusetts Avenue, N.W.Suite 800Washington, D.C. 20001
Phone:<PHONE_NUMBER>
eFax.:<PHONE_NUMBER>
<EMAIL_ADDRESS>www.accci.org

<<COETF Example Bench Photos.pdf>>
<<Accident Report Detail _ Occupational Safety and Health Administration (SIC 3312).pdf>>

From: David Ailor<EMAIL_ADDRESS>Sent: Wednesday, August 10, 2022 4:59 PM
To<EMAIL_ADDRESS>'French, Chuck'<EMAIL_ADDRESS><EMAIL_ADDRESS>'Jones, DonnaLee'<EMAIL_ADDRESS><EMAIL_ADDRESS>'Mcginn, Kevin'<EMAIL_ADDRESS>'GABRIELLE RAYMOND'<EMAIL_ADDRESS>'Shappley, Ned'<EMAIL_ADDRESS>Subject: DRAFT LISTS OF COETF AND EPA "DO-OUTS" FROM YESTERDAY'S CALL ON 114 TESTING

Donna Lee et al.:

Thanks again for making the time to meet with the Coke Oven Environmental Task Force (COETF) yesterday to discuss 114 testing the Agency is requesting.  Below, as promised, are draft lists developed by the COETF inclusive of what we believe are the COETF and EPA "do-outs" from the call.  Please let us know ASAP of any errors/omissions you might identify.  Thanks, David Ailor

COETF Do-Outs:

1. Provide close-up images of battery bench showing safety hazards  -  tight spaces, moving equipment, etc.
2. Provide OSHA reports on previous injuries/fatalities
3. Follow-up on EPA request for information on composition/speciation of VOC from byproduct plant processes (LDAR program)

EPA Do-Outs:

1.	Response to COETF's letter requesting changes to the ICR schedule (expedited response requested)
2.	Response to COETF's letter requesting changes to the ICR scope
3.	Provide list of ambient monitoring stations for which EPA already has data 4.	If any interior/fenceline fugitive monitoring remains in the ICR, confirm whether method can be limited to passive samplers and fenceline locations reduced to 1-2 upwind and 1 downwind
5.	Confirm whether EPA will accept USS SCOT plant stack test data in lieu of performing new testing
6.	Confirm whether EPA will accept DTE/EES COG sample data in lieu of performing new testing

David C. Ailor, P.E.
President
American Coke and Coal Chemicals Institute
25 Massachusetts Avenue, N.W.
Suite 800
Washington, D.C. 20001
Phone:<PHONE_NUMBER>
eFax.:<PHONE_NUMBER>
<EMAIL_ADDRESS>www.accci.org


[Federal Register Volume 85, Number 195 (Wednesday, October 7, 2020)]
[Notices]
[Pages 63286-63288]
[FR Doc No: 2020-22191]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2020-N-1990]

Fee Rate for Using a Tropical Disease Priority Review Voucher in
Fiscal Year 2021

AGENCY: Food and Drug Administration, Health and Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or the Agency) is
announcing the fee rates for using a tropical disease priority review
voucher for fiscal year (FY) 2021. The Federal Food, Drug, and Cosmetic
Act (FD&C Act), as amended by the Food and Drug Administration
Amendments Act of 2007 (FDAAA), authorizes FDA to determine and collect
priority review user fees for certain applications for review of drug
and biological products when those applications use a tropical disease
priority review voucher. These vouchers are awarded to the sponsors of
certain tropical disease product applications submitted after September
27, 2007, the enactment date of FDAAA, upon FDA approval of such
applications. The amount of the fee submitted to FDA with applications
using a tropical disease priority review voucher is determined each
fiscal year based on the difference between the average cost incurred
by FDA to review a human drug application designated as priority review
in the previous fiscal year and the average cost incurred in the review
of an application that is not subject to priority review in the
previous fiscal year. This notice establishes the tropical disease
priority review fee rate for FY 2021 and outlines the payment
procedures for such fees.

FOR FURTHER INFORMATION CONTACT: Andrew Bank, Office of Financial
Management, Food and Drug Administration, 4041 Powder Mill Rd., Rm.
62019A, Beltsville, MD, 20705-4304,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Background

    Section 1102 of FDAAA (Pub. L. 110-85) added section 524 to the
FD&C Act (21 U.S.C. 360n). In section 524, Congress encouraged
development of new drug and biological products for prevention and
treatment of tropical diseases by offering additional incentives for
obtaining FDA approval of such products. Under section 524, the sponsor
of an eligible human drug application submitted after September 27,
2007, for a tropical disease (as defined in section 524(a)(3) of the
FD&C Act) shall receive a priority review voucher upon approval of the
tropical disease product application (as defined in section 524(a)(4)
of the FD&C Act), assuming other criteria are met. The recipient of a
tropical disease priority review voucher may either use the voucher for
a future human drug application submitted to FDA under section
505(b)(1) of the FD&C Act (21 U.S.C. 355(b)(1)) or section 351(a) of
the Public Health Service Act (PHS Act) (42 U.S.C. 262), or transfer
(including by sale) the voucher to another party. The voucher may be
transferred repeatedly until it ultimately is used for a human drug
application submitted to FDA under section 505(b)(1) of the FD&C Act or
section 351(a) of the PHS Act. A priority review is a review conducted
with a Prescription Drug User Fee Act (PDUFA) goal date of 6 months
after the receipt or filing date, depending upon the type of
application. Information regarding the PDUFA goals is available at:
https://www.fda.gov/media/99140/download.
    The sponsor that uses a priority review voucher is entitled to a
priority review but must pay FDA a priority review user fee in addition
to any other fee required by PDUFA. FDA published guidance on its
website about how this tropical disease priority review voucher program
operates (available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/tropical-disease-priority-review-vouchers).
    This notice establishes the tropical disease priority review fee
rate for FY 2021 as $1,360,879 and outlines FDA's process for
implementing the collection of the priority review user fees. This rate
is effective on October 1, 2020, and will remain in effect through
September 30, 2021, for applications submitted with a tropical disease
priority review voucher.

II. Tropical Disease Priority Review User Fee Rate for FY 2021

    FDA interprets section 524(c)(2) of the FD&C Act as requiring that
FDA determine the amount of the tropical disease priority review user
fee each fiscal year based on the difference between the average cost
incurred by FDA in the review of a human drug application subject to
priority review in the previous fiscal year and the average cost
incurred by FDA in the review of a human drug application that is not
subject to priority review in the previous fiscal year.
    A priority review is a review conducted with a PDUFA goal date of 6
months after the receipt or filing date, depending on the type of
application. As described in the PDUFA goals letter, FDA has committed
to reviewing and acting on 90 percent of the applications granted
priority review status within this expedited timeframe. Normally, an
application for a human drug or biological product will qualify for
priority review if the product is intended to treat a serious condition
and, if approved, would provide a significant improvement in safety or
effectiveness. An application that does not receive a priority
designation receives a standard review. As described in the PDUFA goals
letter, FDA has committed to reviewing and acting on 90 percent of
standard applications within 10 months of the receipt or filing date,
depending on the type of application. A priority review involves a more
intensive level of effort and a higher level of resources than a
standard review.
    FDA is setting fees for FY 2021, which is to be based on standard
cost data from the previous fiscal year, FY 2020. However, the FY 2020
submission cohort has not been closed out yet, thus the cost data for
FY 2020 are not complete. The latest year for which FDA has complete
cost data is FY 2019. Furthermore, because FDA has never tracked the
cost of reviewing applications that get priority review as a separate
cost subset, FDA estimated this cost based on other data that the
Agency has tracked. The Agency expects all applications that received
priority review would contain clinical data. The application categories
with clinical data for which FDA tracks the cost of review are: (1) New
drug applications (NDAs) for a new molecular entity (NME) with clinical
data and (2) biologics license applications (BLAs).
    The total cost for FDA to review NME NDAs with clinical data and
BLAs in FY 2019 was $199,369,923. There was a

total of 70 applications in these two categories (49 NME NDAs with
clinical data and 21 BLAs). (Note: these numbers exclude the
President's Emergency Plan for AIDS Relief NDAs; no investigational new
drug review costs are included in this amount.) Of these applications,
44 (32 NDAs and 12 BLAs) received priority review and the remaining 26
(17 NDAs and 9 BLAs) received standard reviews. Because a priority
review compresses a review that ordinarily takes 10 months into 6
months, FDA estimates that a multiplier of 1.67 (10 months divided by 6
months) should be applied to non-priority review costs in estimating
the effort and cost of a priority review as compared to a standard
review. This multiplier is consistent with published research on this
subject, which supports a priority review multiplier in the range of
1.48 to 2.35 (Ref. 1). Using FY 2019 figures, the costs of a priority
and standard review are estimated using the following formula:
(44 [alpha] x 1.67) + (26 [alpha]) = $199,369,923

where ``[alpha]'' is the cost of a standard review and ``[alpha]
times 1.67'' is the cost of a priority review. Using this formula,
the cost of a standard review for NME NDAs and BLAs is calculated to
be $2,004,121 (rounded to the nearest dollar) and the cost of a
priority review for NME NDAs and BLAs is 1.67 times that amount, or
$3,346,882 (rounded to the nearest dollar). The difference between
these two cost estimates, or $1,342,761, represents the incremental
cost of conducting a priority review rather than a standard review.

    For the FY 2021 fee, FDA will need to adjust the FY 2019
incremental cost by the average amount by which FDA's average costs
increased in the 3 years prior to FY 2020, to adjust the FY 2019 amount
for cost increases in FY 2020. That adjustment, published in the
Federal Register on August 3, 2020 (see 85 FR 46651), setting FY 2021
PDUFA fees, is 1.3493 percent for the most recent year, not compounded.
Increasing the FY 2019 incremental priority review cost of $1,342,761
by 1.3493 percent (or 0.013493) results in an estimated cost of
$1,360,879 (rounded to the nearest dollar). This is the tropical
disease priority review user fee amount for FY 2021 that must be
submitted with a priority review voucher for a human drug application
in FY 2021, in addition to any PDUFA fee that is required for such an
application.

III. Fee Rate Schedule for FY 2021

    The fee rate for FY 2021 is set out in table 1:

     Table 1--Tropical Disease Priority Review Schedule for FY 2021
------------------------------------------------------------------------
                                                         Priority review
                      Fee category                       fee rate for FY
                                                               2021
------------------------------------------------------------------------
Application submitted with a tropical disease priority       $1,360,879
 review voucher in addition to the normal PDUFA fee....
------------------------------------------------------------------------

IV. Implementation of Tropical Disease Priority Review User Fee

    Under section 524(c)(4)(A) of the FD&C Act, the priority review
user fee is due upon submission of a human drug application for which
the priority review voucher is used. Section 524(c)(4)(B) of the FD&C
Act specifies that the application will be considered incomplete if the
priority review user fee and all other applicable user fees are not
paid in accordance with FDA payment procedures. In addition, FDA may
not grant a waiver, exemption, reduction, or refund of any fees due and
payable under section 524 of the FD&C Act (see section 524(c)(4)(C)),
and FDA may not collect priority review voucher fees ``except to the
extent provided in advance in appropriation Acts.'' (Section
524(c)(5)(B) of the FD&C Act.)
    The tropical disease priority review fee established in the new fee
schedule must be paid for any application that is received on or after
October 1, 2020, and submitted with a priority review voucher. This fee
must be paid in addition to any other fee due under PDUFA. Payment
should be made in U.S. currency by electronic check, check, bank draft,
wire transfer, credit card, or U.S. postal money order payable to the
order of the Food and Drug Administration. The preferred payment method
is online using electronic check (Automated Clearing House (ACH) also
known as eCheck). Secure electronic payments can be submitted using the
User Fees Payment Portal at https://userfees.fda.gov/pay. (Note: only
full payments are accepted. No partial payments can be made online).
Once you search for your invoice, select ``Pay Now'' to be redirected
to Pay.gov. Note that electronic payment options are based on the
balance due. Payment by credit card is available for balances that are
less than $25,000. If the balance exceeds this amount, only the ACH
option is available. Payments should be made using U.S bank accounts as
well as U.S. credit cards.
    FDA has partnered with the U.S. Department of the Treasury to use
Pay.gov, a web-based payment application, for online electronic
payment. The Pay.gov feature is available on the FDA website after the
user fee identification (ID) number is generated.
    If paying by paper check, the user fee ID number should be included
on the check, followed by the words ``Tropical Disease Priority
Review.'' All paper checks should be in U.S. currency from a U.S. bank
made payable and mailed to: Food and Drug Administration, P.O. Box
979107, St. Louis, MO 63197-9000.
    If checks are sent by a courier that requests a street address, the
courier can deliver the checks to: U.S. Bank, Attention: Government
Lockbox 979107, 1005 Convention Plaza, St. Louis, MO 63101. (Note: This
U.S. Bank address is for courier delivery only.) If you have any
questions concerning courier delivery, contact the U.S. Bank at 314-
418-4013. (This telephone number is only for questions about courier
delivery.) The FDA post office box number (P.O. Box 979107) must be
written on the check. If needed, FDA's tax identification number is 53-
0196965.
    If paying by wire transfer, please reference your unique user fee
ID number when completing your transfer. The originating financial
institution may charge a wire transfer fee. If the financial
institution charges a wire transfer fee, it is required to add that
amount to the payment to ensure that the invoice is paid in full. The
account information is as follows: U.S. Dept. of the Treasury, TREAS
NYC, 33 Liberty St., New York, NY 10045, Account Number: 75060099,
Routing Number: 021030004, SWIFT: FRNYUS33.

V. Reference

    The following reference is on display with the Dockets Management
Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852,<PHONE_NUMBER>, and is available for viewing
by interested persons between 9 a.m. and 4 p.m., Monday through Friday;
it is not available electronically at https://www.regulations.gov as
this reference is

copyright protected. FDA has verified the website address, as of the
date this document publishes in the Federal Register, but websites are
subject to change over time.

1. Ridley, D.B., H.G. Grabowski, and J.L. Moe, ``Developing Drugs
for Developing Countries,'' Health Affairs, vol. 25, no. 2, pp. 313-
324, 2006, available at: https://www.healthaffairs.org/doi/full/10.1377/hlthaff.25.2.313.

    Dated: October 2, 2020.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2020-22191 Filed 10-2-20; 4:15 pm]
BILLING CODE 4164-01-P


Chemical. Persons shall remit an initial fee of $945,000, a second
payment of $945,000 and final payment to total 50% of the actual costs
of this activity, in accordance with the procedures in paragraph (g) of
this section. The final payment amount will be determined by EPA, and
EPA will issue an invoice to the requesting manufacturer.
    (xiv) Manufacturer-requested risk evaluation of a non-work plan
chemical. Persons shall remit an initial fee of $1,890,000, a second
payment of $1,890,000, and final payment to total 100% of the actual
costs of the activity, in accordance with the procedures in paragraph
(g) of this section. The final payment amount will be determined by
EPA, and EPA will issue an invoice to the requesting manufacturer.
* * * * *
    (d) Fees for 2025 fiscal year and beyond. (1) Fees for the 2025 and
later fiscal years will be adjusted on a three-year cycle by
multiplying the fees in paragraph (c) of this section by the current
PPI index value with a base year of 2022 using the following formula:

    FA = F x I

Where:

FA = the inflation-adjusted future year fee amount.
F = the fee specified in paragraph (c) of this section.
I = Producer Price Index for Chemicals and Allied Products inflation
value with 2022 as a base year.

    (2) Updated fee amounts for PMNs, SNUNs, MCANs, exemption notices,
exemption applications, bona fide intent to manufacture (including
import) a chemical substance, notice of commencement of manufacture or
import, and manufacturer-requested chemical risk evaluation requests
apply to submissions received by the Agency on or after October 1 of
every three-year fee adjustment cycle beginning in fiscal year 2022
(October 1, 2021). Updated fee amounts also apply to test rules, test
orders, enforceable consent agreements and EPA-initiated chemical
evaluations that are ``noticed'' on or after October 1 of every three-
year fee adjustment cycle, beginning in fiscal 2022.
    (3) The Agency will initiate public consultation through notice-
and-comment rulemaking prior to making fee adjustments beyond
inflation. If it is determined that no additional adjustment is
necessary beyond for inflation, EPA will provide public notice of the
inflation-adjusted fee amounts most likely through posting to the
Agency's web page by the beginning of each three-year fee adjustment
cycle (October 1, 2024, October 1, 2027, etc.). If the Agency
determines that adjustments beyond inflation are necessary, EPA will
provide public notice of that determination and the process to be
followed to make those adjustments.
* * * * *
    (f) * * *
    (2) * * *
    (i) The consortium must identify a principal sponsor and provide
notification to EPA that a consortium has formed. The notification must
be accomplished within 90 days of the publication date of a test rule
under section 4 of the Act, or within 90 days of the issuance of a test
order under Section 4 of the Act, or within 90 days of the signing of
an enforceable consent agreement under section 4 of the Act. EPA may
permit additional entities to join an existing consortium prior to the
expiration of the notification period if the principal sponsor provides
updated notification.
* * * * *
    (3) * * *
    (i) Notification must be provided to EPA that a consortium has
formed. The notification must be accomplished within 90 days of the
publication of the final scope of a chemical risk evaluation under
section 6(b)(4)(D) of the Act or within 90 days of EPA providing
notification to a manufacturer that a manufacturer-requested risk
evaluation has been granted.
* * * * *
    (4)(i) If multiple persons are subject to fees triggered by section
4 or 6(b) of the Act and no consortium is formed, EPA will determine
the portion of the total applicable fee to be remitted by each person
subject to the requirement. Each person's share of the applicable fees
triggered by section 4 of the Act specified in paragraph (c) of this
section shall be in proportion to the total number of manufacturers
and/or processors of the chemical substance, with lower fees for small
businesses:

[GRAPHIC] [TIFF OMITTED] TP11JA21.020

    (ii) Each person's share of the applicable fees triggered by
section 6(b) of the Act specified in paragraph (c) of this section
shall be in proportion to the total number of manufacturers of the
chemical substance, with lower fees for small businesses:
[GRAPHIC] [TIFF OMITTED] TP11JA21.021

Where:

Fs = the total fee required under paragraph (c) of this
section by a person(s) who qualifies as a small business concern
under Sec.  700.43 of this chapter.
Fo = the total fee required under paragraph (c) of this
section by person(s) other than a small business concern.
Vs = the production volume of a person who qualifies as a
small business concern under paragraph (c) as a percentage of the
total production volume as defined in Sec.  700.43 of person(s) who
qualify as a small business concern under paragraph (c) of this
section.
Vo = the production volume of a person other than a small
business concern as a percentage of the total production volume as
defined in Sec.  700.43 of person(s) other than a small business
concern.

Ps = the portion of the fee under paragraph (c) of this
section that is owed by a person who qualifies as a small business
concern under Sec.  700.43 of this chapter.
Po = the portion of the fee owed by a person other than a
small business concern.
F = the total fee required under paragraph (c) of this section.
Mt = the total number of persons subject to the fee
requirement.
Ms = the number of persons subject to the fee requirement
who qualify as a small business concern.

    (5) * * *
    (iv) Reallocate the remaining fee across those remaining
individuals and groups based on the portion of total production volume
as defined in Sec.  700.43, considering the production volume of each
manufacturer not in a consortium and the total production volume of the
manufacturers in a consortium; and
* * * * *
    (g) * * *
    (3) * * *
    (iv) Risk evaluations. (A) For EPA-initiated risk evaluations, the
applicable fee specified in paragraph (c) of this section shall be paid
in two installments, with the first payment of 50% due 180 days after
publishing the final scope of a risk evaluation and the second payment
for the remainder of the fee due 545 days after publishing the final
scope of a risk evaluation under section 6(b)(4)(D) of the Act.
    (B) * * *
    (1) The applicable fee specified in paragraph (c) of this section
shall be paid in three installments. The first payment shall be due no
later than 180 days after EPA provides the submitting manufacture(s)
notice that it has granted the request.
    (2) The second payment shall be due no later than 545 days after
EPA provides the submitting manufacturer(s) notice that it has granted
the request.
    (3) The final payment shall be due no later than 30 days after EPA
publishes the final risk evaluation.
* * * * *
    (5) * * *
    (ii) Each person who remits the fee identified in paragraph (c)(1)
of this section for a LVE, LoREX, TERA, TME, or Tier II exemption
request under TSCA section 5 shall insert a check mark for the
statement, ``The company named in part 1, section A is a small business
concern under Sec.  700.43 and has remitted a fee of $940 in accordance
with Sec.  700.45(c).'' in the exemption application.
* * * * *
    (v) Each person who remits the fee identified in paragraph (c)(1)
of this section for a bona fide intent to manufacture (including
import) a chemical substance shall insert a check mark for the
statement, ``The company named in part 1, section A is a small business
concern under Sec.  700.43 and has remitted a fee of $90 in accordance
with Sec.  700.45(c).'' when submitting a request in accordance with
Sec.  720.25(b)(2) of this chapter.
    (vi) Each person who remits the fee identified in paragraph (c)(1)
of this section for a notice of commencement of manufacture or import
shall insert a check mark for the statement, ``The company named in
part 1, section A is a small business concern under Sec.  700.43 and
has remitted a fee of $90 in accordance with Sec.  700.45(c).'' when
submitting a notice in accordance with Sec.  720.102(d)(2) of this
chapter.
    (6) * * *
    (ii) Each person who remits a fee identified in paragraph (c)(2) of
this section for a LVE, LoREX, TERA, TME, or Tier II exemption request
under TSCA section 5 shall insert a check mark for the statement, ``The
company named in part 1, section A has remitted the fee of $4,700
specified in Sec.  700.45(c).'' in the exemption application.
* * * * *
    (v) Each person who remits the fee identified in paragraph (c)(2)
of this section for a bona fide intent to manufacture (including
import) a chemical substance shall insert a check mark for the
statement, ``The company named in part 1, section A has remitted the
fee of $500 in accordance with Sec.  700.45(c).'' when submitting a
request in accordance with Sec.  720.25(b)(2) of this chapter.
    (vi) Each person who remits the fee identified in paragraph (c)(2)
of this section for a notice of commencement of manufacture or import
shall insert a check mark for the statement, ``The company named in
part 1, section A has remitted the fee of $500 in accordance with Sec.
700.45(c).'' when submitting a notice in accordance with Sec.
720.102(d)(2) of this chapter.
* * * * *
[FR Doc. 2020-28585 Filed 1-8-21; 8:45 am]
BILLING CODE 6560-50-P


[Federal Register Volume 75, Number 67 (Thursday, April 8, 2010)]
[Proposed Rules]
[Pages 17891-17892]
[FR Doc No: 2010-8016]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Docket No. FAA-2010-0095; Airspace Docket No. 10-ASO-18]

Amendment of Class D Airspace; Goldsboro, NC

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice of proposed rulemaking (NPRM).

-----------------------------------------------------------------------

SUMMARY: This action proposes to amend the Class D airspace at Seymour
Johnson AFB, Goldsboro, NC, to reflect the part-time operating status
of the control tower, enhancing the safety and management of aircraft
operations.

DATES: Comments must be received on or before May 24, 2010.

ADDRESSES: Send comments on this proposal to: U.S. Department of
Transportation, Docket Operations, West Building Ground Floor, Room
W12-140, 1200 New Jersey Avenue, SE., Washington, DC 20590-0001;
Telephone: 1-800-647-5527; Fax:<PHONE_NUMBER>. You must identify the
Docket Number FAA-2010-0095; Airspace Docket No. 10-ASO-18, at the
beginning of your comments. You may also submit and review received
comments through the Internet at http://www.regulations.gov.

FOR FURTHER INFORMATION CONTACT: Melinda Giddens, Operations Support
Group, Eastern Service Center, Federal Aviation Administration, P.O.
Box 20636, Atlanta, Georgia 30320; telephone<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

Comments Invited

    Interested persons are invited to comment on this rule by
submitting such written data, views, or arguments, as they may desire.
Comments that provide the factual basis supporting the views and
suggestions presented are particularly helpful in developing reasoned
regulatory decisions on the proposal. Comments are specifically invited
on the overall regulatory, aeronautical, economic, environmental, and
energy-related aspects of the proposal.
    Communications should identify both docket numbers (FAA Docket No.
FAA-2010-0095; Airspace Docket No. 10-ASO-18) and be submitted in
triplicate to the Docket Management System (see ADDRESSES section for
address and phone number). You may also submit comments through the
Internet at http://www.regulations.gov.
    Commenters wishing the FAA to acknowledge receipt of their comments
on this action must submit with those comments a self-addressed stamped
postcard on which the following statement is made: ``Comments to Docket
No. FAA-2010-0095; Airspace Docket No. 10-ASO-18.'' The postcard will
be date/time stamped and returned to the commenter.
    All communications received before the specified closing date for
comments will be considered before taking action on the proposed rule.
The proposal contained in this notice may be changed in light of the
comments received. A report summarizing each substantive public contact
with FAA personnel concerned with this rulemaking will be filed in the
docket.

Availability of NPRMs

    An electronic copy of this document may be downloaded from and
comments submitted through http://

www.regulations.gov. Recently published rulemaking documents can also
be accessed through the FAA's Web page at http://www.faa.gov/airports_airtraffic/air_traffic/publications/airspace_amendments/.
    You may review the public docket containing the proposal, any
comments received and any final disposition in person in the Dockets
Office (see the ADDRESSES section for address and phone number) between
9 a.m. and 5 p.m., Monday through Friday, except Federal Holidays. An
informal docket may also be examined during normal business hours at
the office of the Eastern Service Center, Federal Aviation
Administration, Room 210, 1701 Columbia Avenue, College Park, Georgia
30337.
    Persons interested in being placed on a mailing list for future
NPRMs should contact the FAA's Office of Rulemaking,<PHONE_NUMBER>, to
request a copy of Advisory Circular No. 11-2A, Notice of Proposed
Rulemaking Distribution System, which describes the application
procedure.

The Proposal

    The FAA is considering an amendment to Title 14, Code of Federal
Regulations (14 CFR) part 71 to amend Class D airspace at Seymour
Johnson AFB, Goldsboro, NC, to reflect the part-time operations of the
airport control tower, establishing in advance the dates and times by a
Notice to Airmen.
    Class D airspace designations are published in Paragraph 5000 of
FAA Order 7400.9T, signed August 27, 2009, and effective September 15,
2009, which is incorporated by reference in 14 CFR 71.1. The Class D
airspace designation listed in this document will be published
subsequently in the Order.
    The FAA has determined that this proposed regulation only involves
an established body of technical regulations for which frequent and
routine amendments are necessary to keep them operationally current.
It, therefore, (1) is not a ``significant regulatory action'' under
Executive Order 12866; (2) is not a ``significant rule'' under DOT
Regulatory Policies and Procedures (44 FR 11034; February 26, 1979);
and (3) does not warrant preparation of a Regulatory Evaluation as the
anticipated impact is so minimal. Since this is a routine matter that
will only affect air traffic procedures and air navigation, it is
certified that this proposed rule, when promulgated, would not have a
significant economic impact on a substantial number of small entities
under the criteria of the Regulatory Flexibility Act.
    The FAA's authority to issue rules regarding aviation safety is
found in Title 49 of the United States Code. Subtitle I, section 106
describes the authority of the FAA Administrator. Subtitle VII,
Aviation Programs, describes in more detail the scope of the agency's
authority. This proposed rulemaking is promulgated under the authority
described in subtitle VII, part A, subpart I, section 40103. Under that
section, the FAA is charged with prescribing regulations to assign the
use of airspace necessary to ensure the safety of aircraft and the
efficient use of airspace. This proposed regulation is within the scope
of that authority as it would amend Class D airspace at Seymour Johnson
AFB, Goldsboro, NC.

Lists of Subjects in 14 CFR Part 71

    Airspace, Incorporation by reference, Navigation (air).

The Proposed Amendment

    Accordingly, pursuant to the authority delegated to me, the Federal
Aviation Administration proposes to amend 14 CFR part 71 as follows:

PART 71--DESIGNATION OF CLASS A, B, C, D AND E AIRSPACE AREAS; AIR
TRAFFIC SERVICE ROUTES; AND REPORTING POINTS

    1. The authority citation for part 71 continues to read as follows:

    Authority:  49 U.S.C. 106(g); 40103, 40113, 40120; E.O. 10854,
24 FR 9565, 3 CFR, 1959-1963 Comp., p. 389.

Sec.  71.1  [Amended]

    2. The incorporation by reference in 14 CFR 71.1 of Federal
Aviation Administration Order 7400.9T, Airspace Designations and
Reporting Points, signed August 27, 2009, effective September 15, 2009,
is amended as follows:

Paragraph 5000 Class D Airspace.

* * * * *

ASO NC D Goldsboro, NC [Amended]

Seymour Johnson AFB, NC
    (Lat. 35[deg]20'22'' N., long. 77[deg]57'38'' W.)

    That airspace extending upward from the surface to and including
2,600 feet MSL within a 5.7-mile radius of Seymour Johnson AFB. This
Class D airspace area is effective during the specific dates and
times established in advance by a Notice to Airmen. The effective
dates and times will thereafter be continuously published in the
Airport/Facility Directory.

    Issued in College Park, Georgia, on March 31, 2010.
Barry A. Knight,
Acting Manager, Operations Support Group, Eastern Service Center, Air
Traffic Organization.
[FR Doc. 2010-8016 Filed 4-7-10; 8:45 am]
BILLING CODE 4910-13-P


[Federal Register Volume 79, Number 224 (Thursday, November 20, 2014)]
[Notices]
[Pages 69187-69188]
[FR Doc No: 2014-27436]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Railroad Administration

[Docket No. FRA-2014-0011-N-21]

Proposed Agency Information Collection Activities; Comment
Request

AGENCY: Federal Railroad Administration (FRA), Department of
Transportation (DOT).

ACTION: Notice and request for comments.

-----------------------------------------------------------------------

SUMMARY: In compliance with the Paperwork Reduction Act of 1995, this
notice announces that the renewal Information Collection Requests
(ICRs) abstracted below are being forwarded to the Office of Management
and Budget (OMB) for review and comment. The ICR describes the nature
of the information collection and its expected burden. The Federal
Register notice with a 60-day comment period soliciting comments on the
following collection of information was published on September 3, 2014
(79 FR 52409).

DATES: Comments must be submitted on or before December 22, 2014.

FOR FURTHER INFORMATION CONTACT: Mr. Robert Brogan, Office of Planning
and Evaluation Division, RRS-21, Federal Railroad Administration, 1200
New Jersey Ave. SE., Mail Stop 25, Washington, DC 20590 (Telephone:
(202) 493-6292), or Ms. Kimberly Toone, Office of Information
Technology, RAD-20, Federal Railroad Administration, 1200 New Jersey
Ave. SE., Mail Stop 35, Washington, DC 20590 (Telephone: (202) 493-
6132). (These telephone numbers are not toll-free.)

SUPPLEMENTARY INFORMATION: The Paperwork Reduction Act of 1995 (PRA),
Public Law 104-13, sec. 2, 109 Stat. 163 (1995) (codified as revised at

44 U.S.C. 3501-3520), and its implementing regulations, 5 CFR part
1320, require Federal agencies to issue two notices seeking public
comment on information collection activities before OMB may approve
paperwork packages. 44 U.S.C. 3506, 3507; 5 CFR 1320.5, 1320.8(d)(1),
1320.12. On September 3, 2014, FRA published a 60-day notice in the
Federal Register soliciting comment on ICR that the agency is seeking
OMB approval. See 79 FR 52409. FRA received no comments in response to
this notice.
    Before OMB decides whether to approve these proposed collections of
information, it must provide 30 days for public comment. 44 U.S.C.
3507(b); 5 CFR 1320.12(d). Federal law requires OMB to approve or
disapprove paperwork packages between 30 and 60 days after the 30 day
notice is published. 44 U.S.C. 3507(b)-(c); 5 CFR 1320.12(d); see also
60 FR 44978, 44983, Aug. 29, 1995. OMB believes that the 30 day notice
informs the regulated community to file relevant comments and affords
the agency adequate time to digest public comments before it renders a
decision. 60 FR 44983, Aug. 29, 1995. Therefore, respondents should
submit their respective comments to OMB within 30 days of publication
to best ensure having their full effect. 5 CFR 1320.12(c); see also 60
FR 44983, Aug. 29, 1995.
    The summary below describes the nature of the information
collection request (ICR) and the expected burden. The revised request
is being submitted for clearance by OMB as required by the PRA.
    Title: Roadway Worker Protection.
    OMB Control Number: 2130-0539.
    Abstract: This rule establishes regulations governing the
protection of railroad employees working on or near railroad tracks.
The regulation requires that each railroad devise and adopt a program
of on-track safety to provide employees working along the railroad with
protection from the hazards of being struck by a train or other on-
track equipment. Elements of this on-track safety program include an
on-track safety manual; a clear delineation of employers'
responsibilities, as well as employees' rights and responsibilities
thereto; well-defined procedures for communication and protection; and
annual on-track safety training. The program adopted by each railroad
is subject to review and approval by FRA. Part 214 regulations have
been deemed different enough from the part 213 regulations as to
require a separate and distinct reporting form (new Form FRA F
6180.119). Regardless of discipline, the FRA inspector will complete
the new Roadway Workplace Safety Violation Report Form (FRA F 6180.119)
when recommending civil penalties for part 214 infractions.
    Type of Request: Extension without change of a currently approved
information collection.
    Affected Public: Businesses (Railroads).
    Form(s): FRA F 6180.119.
    Annual Estimated Burden: 845,230 hours.
    Title: Conductor Certification.
    OMB Control Number: 2130-0596.
    Abstract: On November 9, 2011, FRA issued regulations for
certification of conductors, as required by the Rail Safety Improvement
Act of 2008. See 76 FR 69802. This rule requires railroads to have a
formal program for certifying conductors. As part of that program,
railroads are required to have a formal process for training
prospective conductors and determining that all persons are competent
before permitting them to serve as a conductor. FRA issued this
regulation to ensure that only those persons who meet minimum Federal
safety standards serve as conductors, to reduce the rate and number of
accidents and incidents, and to improve railroad safety. Although this
rule does not propose any specific amendments to the regulation
governing locomotive engineer certification, it does highlight areas in
that regulation that may require conforming changes. The information
collected under this rule is used by FRA to ensure that railroads and
their employees fully comply with all the requirements of part 242,
including a conductor certification/recertification program, fitness
requirements, initial and periodic testing of conductors, territorial
qualifications, etc.
    Type of Request: Revision of a currently approved information
collection.
    Affected Public: Businesses (Railroads).
    Form(s): N/A.
    Annual Estimated Burden: 922,317 hours.
    Addressee: Send comments regarding this information collections to
the Office of Information and Regulatory Affairs, Office of Management
and Budget, 725 Seventeenth Street NW., Washington, DC, 20503,
Attention: FRA Desk Officer. Comments may also be sent via email to OMB
at the following address<EMAIL_ADDRESS>    Comments are invited on the following: Whether the proposed
collections of information are necessary for the proper performance of
the functions of the Department, including whether the information will
have practical utility; the accuracy of the Department's estimates of
the burden of the proposed information collections; ways to enhance the
quality, utility, and clarity of the information to be collected; and
ways to minimize the burden of the collections of information on
respondents, including the use of automated collection techniques or
other forms of information technology.
    A comment to OMB is best assured of having its full effect if OMB
receives it within 30 days of publication of this notice in the Federal
Register.

    Authority: 44 U.S.C. 3501-3520.

Rebecca Pennington,
Chief Financial Officer.
[FR Doc. 2014-27436 Filed 11-19-14; 8:45 am]
BILLING CODE 4910-06-P


[Federal Register: June 19, 2008 (Volume 73, Number 119)]
[Rules and Regulations]
[Page 34865-34866]
[DOCID:fr19jn08-13]

-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

33 CFR Part 117

[Docket No. USCG-2008-0478]

Drawbridge Operation Regulations; LaLoutre Bayou, Yscloskey, LA

AGENCY: Coast Guard, DHS.

ACTION: Notice of temporary deviation from regulations; request for
comments.

-----------------------------------------------------------------------

SUMMARY: The Commander, Eighth Coast Guard District, has issued a
temporary deviation from the regulation governing the operation of the
State Route 46 (LA 46) Bridge across LaLoutre Bayou, mile 22.9, at
Yscloskey, St. Bernard Parish, Louisiana. This deviation will test a
change to the drawbridge operation schedule to determine whether a
permanent change to the schedule is needed. This deviation will allow
more efficient use of personnel by requiring a 2 hour notice for night
time openings.

DATES: This deviation is effective from 8 p.m. on June 19, 2008 through
4 a.m. on December 16, 2008.

ADDRESSES: You may submit comments identified by Coast Guard docket
number USCG-2008-0478 to the Docket Management Facility at the U.S.
Department of Transportation. To avoid duplication, please use only one
of the following methods:
    (1) Online: http://www.regulations.gov.
    (2) Mail: Docket Management Facility (M-30), U.S. Department of
Transportation, West Building Ground Floor, Room W12-140, 1200 New
Jersey Avenue, SE., Washington, DC 20590-0001.
    (3) Hand delivery: Room W12-140 on the Ground Floor of the West
Building, 1200 New Jersey Avenue, SE., Washington, DC 20590, between 9
a.m. and 5 p.m., Monday through Friday, except Federal holidays. The
telephone number is<PHONE_NUMBER>.
    (4) Fax:<PHONE_NUMBER>.

FOR FURTHER INFORMATION CONTACT: If you have questions on this test
deviation, call Kay Wade, Bridge Administration Branch, telephone 504-
671-2128. If you have questions on viewing or submitting material to
the docket, call Renee V. Wright, Program Manager, Docket Operations,
telephone<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

Public Participation and Request for Comments

    We encourage you to participate in this action by submitting
comments and related materials. All comments received will be posted,
without change, to http://www.regulations.gov and will include any
personal information you have provided. We have an agreement with the
Department of Transportation (DOT) to use the Docket Management
Facility. Please see DOT's ``Privacy Act'' paragraph below.

Submitting Comments

    If you submit a comment, please include the docket number for this
action (USCG-2008-0478), indicate the specific section of this document
to which each comment applies, and give the reason for each comment. We
recommend that you include your name and a mailing address, an e-mail
address, or a phone number in the body of your document so that we can
contact you if we have questions regarding your submission. You may
submit your comments and material by electronic means, mail, fax, or
delivery to the Docket Management Facility at the address under
ADDRESSES; but please submit your comments and material by only one
means. If you submit them by mail or delivery, submit them in an
unbound format, no larger than 8\1/2\ by 11 inches, suitable for
copying and electronic filing. If you submit them by mail and would
like to know that they reached the Facility, please enclose a stamped,
self-addressed postcard or envelope. We will consider all comments and
material received during the comment period. We may change this
proposed action in view of them.

Viewing Comments and Documents

    To view comments, as well as documents mentioned in this preamble
as being available in the docket, go to http://www.regulations.gov at
any time, click on ``Search for Dockets,'' and enter the docket number
for this action (USCG-2008-0478) in the Docket ID box, and click enter.
You may also visit the Docket Management Facility in Room W12-140 on
the ground floor of the DOT West Building, 1200 New Jersey Avenue, SE.,
Washington, DC 20590, between 9 a.m. and 5 p.m., Monday through Friday,
except Federal holidays.

Privacy Act

    Anyone can search the electronic form of all comments received into
any of our dockets by the name of the individual submitting the comment
(or signing the comment, if submitted on behalf of an association,
business, labor union, etc.). You may review the Department of
Transportation's Privacy Act Statement in the Federal Register
published on April 11, 2000 (65 FR 19477), or you may visit http://
DocketsInfo.dot.gov.

Background and Purpose

    The LA 46 vertical lift span bridge, located on LaLoutre Bayou at
mile 22.9, in Yscloskey, St. Bernard Parish, Louisiana, has a vertical
clearance of 2 feet in the closed position and 53 feet in the open
position. The bridge has a horizontal clearance of 45 feet. The draw of
the LA 46 Bridge opens on signal as required by 33 CFR 117.5. However,
the draw of the bridge has been inoperable since August 2005 due to
damage sustained during Hurricane Katrina.
    Historically, the waterway at the bridge site has been transited by
recreational boaters and fishing vessels. However, there has been no
navigational traffic through the bridge site since it was damaged in
2005.
    Repairs to the bridge have been completed and the Louisiana
Department of Transportation and Development (LDOTD) will soon reopen
the bridge to navigation. LDOTD has requested a change to the
drawbridge operation schedule in order to make more efficient use of
operating resources, while accommodating the flow of vehicular traffic.
    This deviation will test the following change to the drawbridge
operation

schedule: The draw of the LA 46 Bridge, mile 22.9, at Yscloskey, shall
open on signal; except that from 8 p.m. to 4 a.m., the draw shall open
on signal if at least two hours notice is given.
    A Notice of Proposed Rulemaking (USCG-2008-0478) will be issued to
propose a permanent change to the schedule and obtain additional public
comments. The Coast Guard will evaluate public comments from this
Temporary Deviation and the above referenced Notice of Proposed
Rulemaking to determine if a permanent special drawbridge operation
regulation is warranted. The Coast Guard will review bridge tender logs
for requested bridge openings during the time of the Temporary
Deviation. Navigation is not expected to be impacted during the test
schedule period.

Additional Information

    Although this Temporary Deviation will require 2 hours advance
notice for openings between 8 p.m. and 4 a.m., an alternate route, via
Yscloskey Bayou, to the Mississippi River Gulf Outlet and Lake Borgne
is available with no additional transit time. Additionally, most users
of this waterway are able to give notice prior to transiting through
the bridge. Vessels are not able to pass underneath the bridge when
closed due to a vertical clearance of only 2 feet. Before the effective
period, we will issue maritime advisories widely available to users of
the waterway.
    In accordance with 33 CFR 117.35(e), the drawbridge must return to
its regular operating schedule immediately at the end of the designated
time period. This deviation from the operating regulations is
authorized under 33 CFR 117.35.

    Dated: June 9, 2008.
David M. Frank,
Bridge Administrator, U.S. Coast Guard.
[FR Doc. E8-13864 Filed 6-18-08; 8:45 am]

BILLING CODE 4910-15-P